
MBF Therapeutics: Innovating cancer care for animals through advanced veterinary immunotherapies.
Founded with a mission to revolutionize veterinary medicine, MBF Therapeutics focuses on advancing cancer care for companion animals through innovative immunotherapeutic products. The company's vision is to set new standards in animal healthcare by leveraging cutting-edge scientific research and technology. MBF Therapeutics offers a range of advanced veterinary immunotherapies designed to treat various forms of cancer in pets, aiming to improve both the quality and longevity of animal lives.
MBF Therapeutics has attracted notable investors and experts in veterinary medicine and biotechnology, contributing to its rapid growth and development. The company has achieved significant milestones, including successful clinical trials and regulatory approvals for its products. By pioneering new treatments in veterinary oncology, MBF Therapeutics has made a substantial impact on the field, offering hope and improved outcomes for pets diagnosed with cancer.
Vetmab Biosciences

Vetigenics
vetigenics.com

Curelab Veterinary

MBX Biosciences
mbxbio.com

MBC Pharma
mbcpharma.com

WayPath Pharma
waypathpharma.com

PanTher Therapeutics
panthertx.com

Pelican Therapeutics

Mobius Therapeutics

LTZ Therapeutics

Animal Life Sciences

Elias Animal Health

Immune-Onc Therapeutics
immuneonc.com

Imvaq Therapeutics

Angarus Therapeutics
angarustx.com
Companies similar to MBF Therapeutics include Vetmab Biosciences, Vetigenics, Curelab Veterinary and MBX Biosciences.
MBF Therapeutics was founded in 2008.
MBF Therapeutics' headquarters is located in Ambler, PA, US.
MBF Therapeutics' most recent funding round was for $256k (USD) in December 2021.
As of Dec 21, 2021, MBF Therapeutics has raised a total of $851k (USD).
MBF Therapeutics has 7 employees as of Feb 5, 2024.